|
|
Article: MediciNova Presents MN-029 Phase I Safety and Tumor Blood Flow Reduction Results in Cancer Patients at ASCO Annual Meeting.
- Article from:
- PR Newswire
- Article date:
- June 4, 2006
CopyrightCOPYRIGHT 2006 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO, June 4 /PRNewswire/ -- MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today reported presentation of the results from the first of its Phase I clinical trials of MN-029 in solid tumor cancer patients at the 2006 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, Georgia. MN-029 significantly reduced tumor blood flow, a pharmacologic marker believed to predict clinical efficacy, at doses that were well tolerated, including doses below the maximum tolerated dose.
"By taking advantage of the unique anatomy of tumor blood ...